Endo to acquire Boca for $225 million
Endo Health Solutions announced yesterday that its generics subsidiary, Qualitest, is to acquire privately held Boca Pharmacal for $225 million in cash.
Boca Pharmacal is a specialty generics company that focuses on niche areas, including controlled substances, semisolid drugs and solutions. Endo believes the acquisition will ‘accelerate the growth of Qualitest in 2014’.
Endo’s Qualitest unit snags niche generics player for $225M (FiercePharma)
Endo to Acquire Specialty Generics Company Boca Pharmacal (Press release)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.